NEW YORK – BioMérieux reported today that its fourth quarter revenues rose 11 percent year over year driven by sales of molecular biology reagents and microbiology instruments, as well as a strong dynamic in Asia Pacific.
For the three months ended Dec. 31, BioMérieux reported revenues of €746.8 million ($810.8 million), up 11 percent on a reported basis, or 8 percent at constant exchange rates and scope of consolidation, from €672.4 million in the prior-year period.